The Rundown Novo Nordisk Sues Hims Over Copycat Drugs, Super Bowl Breaks Betting Record
14 snips
Feb 9, 2026 A market recap on last week’s rally and why traders remain cautious. Coverage of Novo Nordisk suing Hims over alleged copycat GLP-1 weight-loss drugs and related regulatory fallout. China asking banks to curb new U.S. Treasury purchases and how that rattles bond markets. A record-breaking Super Bowl for betting and the rise of prediction markets.
AI Snips
Chapters
Transcript
Episode notes
Watch Macro Data After The Big Bounce
- Expect a choppy market week after a big one-day relief rally, especially with key jobs and CPI reports due.
- Monitor earnings, the delayed January jobs report, and Friday's CPI before making major allocation moves.
Host Shout-Out To Platform Partner
- Zaid Admani thanks Public and highlights platform features like direct indexing and AI research tools.
- He notes Public is offering a 1% match on transfers, calling it a good time to sign up.
Big Pharma Protects GLP-1 Patents
- Novo Nordisk sued Hims for selling unapproved compound versions of its weight-loss drugs and to block copycat pills.
- The FDA and HHS moved quickly, prompting Hims to scrap a WeGovie pill offer and rattling investors.